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Nausea and Vomiting in Fractionated 
Radiotherapy: a Prospective On-demand Trial of 
Tropisetron Rescue for Non-responders to 
Metoclopramide 
R. Miralbell, P. Coucke, F. Behrouz, N. Blazek, M. Melliger, S. Philipp, 
R. Wickenhauser, S. Gebhard, T. Schwabb, A. Rosset, G. Hagen, P. Douglas, 
S. Bieri, A. Allal, S. Majno and A. Bardina 
A prospective trial was performed to better assess the risk of nausea and vomiting and the rescue value of 
tropisetron (TRO), a 5HT3 receptor antagonist, in 88 patients undergoing fractionated radiotherapy to the 
abdomen or to large supradiaphragmatic fields and failing a first anti-emetic trial with metoclopramide (MET). 
Nausea was graded 0 (absent), 1 (mild), 2 (moderate) and 3 (severe). Nausea requiring anti-emetics (L grade 2) 
was present in 64% of the patients. MET was able to control nausea (I grade 1) in 26 of 58 patients (45%) who 
developed 1 grade 2 nausea during radiation treatment (2 patients vomiting without nausea included). 34 patients 
required TRO, and 31 experienced immediate relief. However, nausea (1 grade 2) recurred in 7 patients from 1 
to 3 weeks after starting, TRO. Sex, age, field type and field size (cm*) did not influence the incidence and severity 
of nausea and vomiting. Only 24188 patients vomited after starting radiotherapy. MET helped to eliminate emesis 
in one third of these patients. TRO helped to control vomiting in 73% of the salvaged patients. Constipation was 
observed in 8 patients on TRO and was a reason to stop the medication in 4 cases. 
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INTRODUCTION 
APPROXIMATELY 50% of patients subjected to a course of frac- 
tionated radiotherapy of the upper abdomen or treated to large 
volumes (e.g. mantle, inverted Y, or hockey stick fields) develop 
nausea nd vomiting [ 11. Metoclopramide (MET) has proved its 
usefulness in half of these patients [ 11. Although MET can be 
associated with sedation and/or extrapyramidal side-effects, 
there is considerable experience in the use of this relatively 
inexpensive medication. T.he 5-HTs receptor antagonists have 
shown an unmatched efficacy in patients undergoing chemo- 
therapy [2, 31, whole-body irradiation [4], and single high-dose 
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radiation to the upper abdomen [5]. Radiation may induce 
nausea and vomiting by triggering the same serotonin receptors 
of the gut wall as chemotherapy. Thus, 5-HTs receptor antagon- 
ists should also be effective anti-emetics in fractionated radio- 
therapy. Two preliminary, non-controlled studies addressing 
this issue have already been published [6, 71. Although these 
studies included a reduced number of patients, all of them 
receiving upfront 5-HT3 receptor antagonists, a success rate of 
80% in preventing nausea nd vomiting was observed. 
In our study, the potential role and efficacy of the 5-HT3 
receptor antagonists against radiation-induced nausea and vom- 
iting were tested with tropisetron (TRO) (Navoban, Sandoz 
Wander-Pharma Ltd, Bern, Switzerland). The choice of TRO 
was mainly based on availability of an oral presentation and 
prescription simplicity assuring compliance (i.e. a single 5-mg 
capsule a day). It is not a controlled randomised study but a 
prospective “on-demand” rescue trial. Patients at risk for nausea 
and vomiting did not receive upfront medication when starting 
radiotherapy. MET was first prescribed if needed. Patients who 
continued to experience nausea or vomiting while on MET were 
rescued with TRO. We assumed that this simple trial would 
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help us to better assess the overall risk of nausea and vomiting, 
and to define those patients potentially benefiting from TRO. 
PATIENTS AND METHODS 
From October 1992 to June 1994, 88 patients from the 
University Hospitals of Geneva and Lausanne agreed to partici- 
pate in this study. Patients at high risk for nausea and vomiting 
during standard fractionated radiotherapy were included: upper 
abdominal, large abdominal and large supradiaphragmatic 
(“mantle”) fields. All patients were treated with single daily 
fractions, 5 days a week, and 1.5-2 Gylfraction. Patients 
undergoing total or hem&body irradiation were excluded. Pati- 
ents receiving abdominal irradiation for bone metastasis or 
painful soft tissue lesions were also excluded to avoid the 
confounding effect of morphine and other analgesics in the 
development and control of nausea and emesis. Simultaneous 
steroids or chemotherapy, however, were not considered reasons 
for exclusion. 9 patients received concomitant 5fluorouracil 
(5FU) during radiotherapy, 1 patient received simultaneous 
cisplatin, and 1 patient was treated with alternating radiotherapy 
and cyclophosphamide doxorubicin. 3 patients received simul- 
taneous teroids and 1 patient interferon. 
A daily status check was performed and a few questions 
concerning the nausea intensity and duration, the daily number 
of emetic episodes and the potential side-effects of the antiemet- 
its were answered by the patients in the presence of a nurse or a 
physician. Nausea was graded 0 (absent), 1 (mild, spontaneous 
relief, normal intake, not requiring medication), 2 (moderate, 
decreased intake, requiring medication), and 3 (severe, continu- 
ous, no significant intake, requiring medication). Vomiting was 
graded according to the number of daily episodes. No upfront 
treatment was given. Patients who developed nausea (i.e. 2 
grade 2) and/or emesis within at least a 24-h period after the start 
of radiotherapy were given the usual recommended ose of MET 
in its oral presentation (10 mg, three times a day, orally) for the 
remainder of the treatment. However, if after a 24-48-h trial of 
MET (or any time thereafter) nausea (2 grade 2) or vomiting 
persisted (or recurred) the patients were given TRO (5 mg, once 
a day, orally) for the remainder of the radiotherapy period. 
The median age was 46 years (range 8-83). There were 64 
males and 24 females. The treated sites and field types are 
presented in Table 1. Treatments were almost always delivered 
with a set of two AP/PA parallel and opposed fields. Field sizes 
were calculated by multiplying the two X and Y field dimensions 

























(cm*), not taking into account the block-related shielded sur- 
faces. The median field size surface was 466.5 cm2 (range 
70-1400). 
The incidence and severity of spontaneous nausea nd vomit- 
ing, and the efficacy of MET or TRO in controlling them is 
reported. Chi-square and two tailed Fisher’s exact tests were 
used to examine the influence of variables such as sex, age, site 
and field size on the incidence of nausea and vomiting. The 
potential inhuence of the severity of nausea (i.e. grade 2 versus 
grade 3) and of the time interval to nausea from the start of 
radiotherapy in response to MET and to TRO was also analysed. 
Side-effects and compliance are also presented. 
RESULTS 
Table 2 shows the incidence of nausea (grade O-3) after 
starting radiotherapy. No nausea (grade 0) or mild nausea (grade 
1, not requiring medication) was observed in 32 cases (36%) 
during the surveillance period. 56 patients required anti-emetics 
because of the onset of grade 2-3 nausea. MET was first 
prescribed to the former 56 patients and to 2 additional patients 
with grade 1 nausea who vomited. MET was sufficient o control 
nausea (i.e. 5 grade 1) in 26/58 (45%) patients treated. The 
remaining 32 patients with continuous 2 grade 2 nausea and 2 
additional patients vomiting but with only mild nausea under 
MET were offered TRO. In this group, 31/34 patients (91%) 
had immediate relief (5 grade 1 nausea). However, 7 patients 
presented a recurrence of 2 grade 2 nausea from 6 to 25 days 
after starting TRO. Figure 1 displays the prevalence of grade 
2-3 nausea versus time after starting TRO. Despite the small 
number of patients at risk for nausea 3 weeks after starting the 
TRO trial, a time-dependent increase in the proportion of 
patients with nausea was observed. A total of 24134 patients 
(71%) had a definite improvement with I grade 1 nausea while 
on TRO. However, among those 24 responders, 4 who stopped 
the medication because of side-effects (while on radiation) 
presented arecurrence of significant nausea shortly after. 
Neither sex, nor age, nor field size influenced the incidence or 
severity of nausea (I grade 1 versus 2 grade 2). Table 3 presents 
the demand of anti-emetics by treated site or field type. We were 
able to find in each site a similar proportion of anti-emetic-free 
patients. Furthermore, a similar proportion of patients in each 
site either never needed anti-emetics or were successfully 
relieved (5 grade 1 nausea) with MET: 21/34 (62%) upper 
abdominal, 25/40 (62%) large abdominal and 8114 (57%) mantle 
fields. 
Almost half of the patients (17136) with grade 2 but only 
one quarter (5/20) with grade 3 nausea at presentation were 
successfully treated with MET. This difference was not statisti- 
cally significant; hence, a relation between severity of nausea 
and likelihood of responding to MET could not be clearly 
demonstrated. The response to MET was also analysed as a 
function of the relation between the time interval between the 
start of radiotherapy and the onset of 2 grade 2 nausea or emesis. 
Fourteen of 24 (58%) MET responders, but 30134 (88%) MET 
failures presented with spontaneous nausea/vomiting during the 
first 5 days of radiotherapy (P = 0.021). Thus, an early onset of 
radiation-induced nausea and/or vomiting suggests a poorer 
response to MET. 
There were no significant differences in the incidence and 
severity of nausea between patients receiving or not receiving 
simultaneous or alternating radiochemotherapy or steroids. 6 
patients never complained of nausea or were controlled with 
MET, whereas 9 patients required TRO. Nausea (B grade 2) 
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Table 2. Nausea: incidence and severity (worst day) 
!icore At onset 
Grade 0 (absent) 21 (24) 
Grade 1 (mild) 11 (12) 
Grade 2 (moderate) 36 (41) 
Grade 3 (severe) 20 (23) 
Total (at risk) 88 













‘ii 56 patients with 2 grade 2 nausea nd 2 patients vomiting but without nausea t 
onset. t 32 patients with 2 grade 2 nausea nd 2 patients vomiting but without nausea 
on MET. 
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Figure 1. Daily proportion of patients on TRO with grade 2-3 
nausea. Figures above the columns represent the ratios between the 
patients with nausea and the ,total patients at risk for a specih Z-day 
time interval. 
recurred in 5 patients on TRO (all of them treated with 5-FU 
and radiotherapy). 
Unlike nausea, vomiting was a rather infrequent event. Table 
4 presents the proportion of patients vomiting while on surveil- 
lance, on MET and on TRO, respectively. Only 24 vomited at 
least once a day after startiug radiotherapy. MET was helpful in 
eliminating the emetic episodes in one third of these patients 
(i.e. 8/24). The remaining 16 MET failures and 6 patients with 
2 grade 2 nausea who vomited for the first time while on MET 
entered the TRO trial. The overall effect of TRO on vomiting 
was a complete remission in 16/22 (73%) patients and a stabilis- 
ation (one daily emetic episode) in the remaining 6 patients. As 
mentioned above, 4 patients discontinued TRO because of side- 
effects and 3 restarted vomiting. 
Two extrapyramidal MET-related events were observed in 2 
patients, respectively. One patient presented with dysarthria, 
the other with facial dyskinetic movements. An additional 
patient complained of dizziness while on MET. Constipation 
was observed in 8 patients on TRO. Four days was the median 
time to constipation (range 2-20). Migraine episodes were also 
observed in 3 additional patients on TRO, 2 of whom were 
already known as chronic migraine patients. 
The above-mentioned TRO-related constipation was the rea- 
son to stop the medication in 4 patients despite a satisfactory 
control of nausea and vomiting. The absence of anti-emetic 
benefit was the reason to discontinue the medication in five TRO 
failures. An additional patient stopped TRO after 10 days 
because of an acute radiation-induced oesophagitis and was 
switched to MET in suppository form. 
DISCUSSION 
Because of patient subjectivity, nausea is a difficult end-point 
to score. It is doubtful whether mild (grade 1) nausea need be 
considered aproblem requiring medical attention. In our grading 
system we deliberately decided not to offer anti-emetics to these 
patients and attributed the same significance to grade 1 as to 
grade 0. In fact, the difference between grade 1 and grade 2 
nausea was frequently based on the patient’s demand for medical 
relief. The distinction between grade 2 and grade 3 was some- 
times difficult to establish. There is, however, a good correlation 
in this study between severe nausea (occurring in 23% of 
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Table 4. Vomiting: incideme and severity (worst day) 
Daily episodes At onset 
Number of patients (%) 
On MET On TRO 
0 64 (73) 8 (27) 16 (73) 
1 12 (14) 16 (53) 6 (27) 
2 7 (8) 4 (13) 0 
23 5 (6) 2 (7) 0 
Total (at risk) 88 30* 22t 
* 24 patients with one or more vomit episodes and 6 patients without vomiting but 
with 2 grade 2 nausea t onset. t 22 patients with one or more vomit episodes on 
MET. 
patients) and any vomiting (occurring in 28% of patients) at treated with lactulose, 4 of our patients stopped the anti-emetic 
onset which would tend to validate this grading system. medication because of this side-effect. 
TRO proved to be very effective in the majority of patients 
failing the MET trial. This efficacy was specially marked during 
the Srst days on TRO. However, a time-dependent nausea 
recurrence was suggested by our data. This could reflect either a 
weakening of the anti-emetic effect over time or a non-admitted 
lack of compliance. The median total duration of radiotherapy 
for the patients who eventually received TRO was rather short 
(26 days). The surveillance period and the MET trial additionally 
shortened the time interval at risk for nausea nd vomiting while 
on TRO (median 12 days). Thus, although one should be 
cautious with conclusions reached with small numbers of pati- 
ents, the possibility of a loss of efficacy over time should be kept 
in mind, especially for long radiotherapy treatments. Sorbe and 
colleagues [6] also observed an increase of nausea from start to 
end of radiotherapy in a group of 20 patients undergoing 
abdominal irradiation for ovarian cancer and receiving upfront 
TRO. 
In summary, while moderate to severe nausea was present in 
almost two thirds of patients undergoing upper abdominal or 
large field (abdominal or “mantle”) irradiation, less than one 
third vomited. No patient- or radiotherapy-related factors were 
found to be predictive in the incidence and severity of nausea 
and vomiting. TRO shows a remarkable rescue potential for 
patients failing MET. The TRO anti-emetic efficacy, however, 
may diminish over long treatment periods. Although TRO 
seems to reduce radiation-induced diarrhoea it may lead to 
constipation. Avoidance of TRO on weekends and the use of 
laxatives for constipated patients can be helpful in relieving this 
problem. To avoid overtreating patients who may never need 
anti-emetics, future trials in patients treated by radiotherapy 
should be confined to those patients actually requiring treatment 
for nausea and vomiting. 
Nutritional problems with weight loss, electrolyte disturb- 
ances and deteriorated quality of life have been mentioned as the 
potential results of continuous severe vomiting during long 
irradiation periods using abdominal fields. In our study, a large 
majority of patients never vomited and only 6% of the patients 
presented three or more daily (worst day) emetic episodes. Thus, 
serious medical problems from vomiting are rather exceptional 
during abdominal irradiation. Fortunately, with the sequential 
use of MET and TRO, vomiting was controlled in all but 6 (7%) 




It has been suggested that the constipating effect of S-HTs 
receptor antagonists can help to control the diarrhoea commonly 
associated with abdominal irradiation. In our study, no patient 
undergoing abdominal irradiation suffered diarrhoea fter TRO. 
8 patients complained, however, of an excessive bowel move- 
ment reduction. A similar situation was reported by Henriksson 
and colleagues with ondansetron, who reported 11/33 cases of 
mild constipation [7]. Unlike their patients who were easily 
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